qxp 1 4 09 23:56 Page 78 78 Hikma Pharmaceuticals PLC Governance Annual report 2008 Directors report The Directors are pleased to present their report and audited financial statements for the year ended 31 December 2008. Business review Directors and their interests The names of the Directors as at the date of this report, The Company is required by the Companies Act 2006 to together with details of their roles, backgrounds and abilities, set out a fair review of the business during the year and a are set out in the Directors biographies on pages 68 and 69. description of the principal risks and uncertainties facing the Details of the independence of Non-Executive Directors are Company, noting the performance and development of the set out in the report on corporate governance on page 72.
Company during the year and the position at the year end.
The Executive and Non-Executive Directors served the The information that fulls these requirements and which is Company throughout the year.
At the 2009 Annual General incorporated into this report by reference, is included in the Meeting, all of the Directors other than Said Darwazah and following sections of the Annual Report: Ronald Goode will retire in accordance with Article 104 of the Articles of Association, and, being eligible, will offer a review of the business and strategy and expected future themselves for re-election.
The explanatory notes to the developments is set out in the Chairmans statement on Notice of Annual General Meeting sets out why the Board pages 6 to 7, the Chief Executives review on pages 28 to 31 believes these Directors should be re-elected.
and the Business and Financial review on pages 34 to 57: Details of Directors share-based incentives and interests the principal risks and uncertainties are set out on pages 50 in the Ordinary Shares of the Company are provided in the to 54 and financial risks are described on pages 54 to 57: Directors remuneration report on pages 90 and 91. key financial performance indicators are described on pages Creditor payment policy 34 to 36: The Companys policy, which is also applied by the Group, is to settle terms of payment with suppliers when agreeing information on environmental, social and community issues the terms of each transaction, ensure that suppliers are made is set out in our Corporate and Social Responsibility report aware of and abide by the terms of payment and abide by on pages 58 to 65, which also provides key performance the terms of payment.
Trade creditors of the Company at indicators in this area: 31 December 2008 were equivalent to 48 days purchases the principal operating subsidiaries are set out on page 152.
2007: 81 days, based on the average daily amount invoiced by suppliers during the year.
Principal activity Charitable and political contributions The principal activities of the Group are the development, During the year the Group made charitable donations of manufacture and marketing of a broad range of generic and approximately $2.4 million 2007: $1.3 million, principally in-licensed pharmaceutical products in solid, semi-solid, to local charities serving the communities in which the liquid and injectable final dosage forms.
[Other disclosures of charitable donations].
are conducted through three business segments: Branded Donations of medicines accounted for approximately Pharmaceuticals, Generic Pharmaceuticals and Injectable $1.4 million 2007: $590,000 of total donations made.
The majority of Hikmas operations are The Group does not make political donations.
in the MENA region, the United States and Europe.
The Groups net sales, gross profit and operating profit Research and Development R&D are shown by business segment in Note 4 to the consolidated The Groups investment in Research and Development financial statements.
during 2008 represented 3.8% of Group revenue 2007: 4.3%.
Further details on the Groups R&D activities can Results and dividends be found on page 38.
The Groups profit for the year attributable to shareholders in 2008 was $57.1 million 2007: $62.6 million.
The Board Going concern is recommending a final dividend of 4.0 cents per share The Directors have formed a judgement, that there is a approximately 2.8 pence.
The proposed final dividend reasonable expectation that the Group has adequate will be paid on 2 June 2009 to shareholders on the register resources to continue in operational existence for the on 1 May 2009, subject to approval at the Annual General foreseeable future, and the Directors continue to adopt the Meeting.
going concern basis in preparing the financial statements.
An interim dividend of 3.5 cents per share was paid on Further details are provided in the Financial risks section 17 October 2008 approximately 1.9 pence per Ordinary of the Financial and Business review on pages 54 to 57.
Share which together with the final dividend, will make a total of 7.5 cents per share for the period 2007: 7.5 cents.
qxp 27 3 09 22:45 Page 79 Hikma Pharmaceuticals PLC 79 Annual report 2008 Capital structure significant agreements and contracts Details of the authorised and issued share capital, together with Due to the nature of the Groups business, members of movements in the issued share capital during the year can be the Group are party to agreements that could alter or found in Note 31 to the consolidated financial statements.
be terminated upon a change of control of the Group The Company has one class of Ordinary Shares which following a takeover.
However, none of these agreements is carries no right to xed income.
Each share carries the right individually deemed to be significant in terms of its potential to one vote at general meetings of the Company.
As at 31 impact on the business of the Group taken as a whole.
December 2008, the Company had 189,237,607 Ordinary The Directors are not aware of any agreements between the Shares of 10 pence each in issue.
During 2008 the Company Company and its Directors or employees that provide for issued 1,503,800 Ordinary Shares pursuant to the exercise of compensation for loss of ofce or employment that occurs options under the Hikma Pharmaceuticals PLC 2004 Stock because of a takeover bid.
Option Plan, and 17,000,000 Ordinary Shares pursuant to a There are no persons with whom the Company has placing to institutional and other shareholders to renance contractual or other arrangements, which are deemed to the debt incurred in respect of the acquisition of the entire be essential to the business of the Company.
issued share capital of Arab Pharmaceutical Manufacturing Co. made in December 2007, undertaken on 17 January 2008.
Pre-emptive issue of Ordinary Shares There are no specic restrictions on the size of a holding During the year under review, and in the period since or on the transfer of shares, which are both governed by the 1 November 2005, the date of the Companys IPO, the general provisions of the Companys Articles of Association Company did not issue any Ordinary Shares pursuant to an and prevailing legislation.
The Directors are not aware of any authority given by shareholders at Annual General Meeting agreements between holders of the Companys shares that to issue Ordinary Shares for cash on a non pre-emptive may have resulted in restrictions on the transfer of securities basis, other than in respect of the placing undertaken on or on voting rights.
No person has any special rights with regard to the control of the Companys share capital and all 17 January 2008, detailed above.
issued shares as fully paid.
Directors indemnities Details of the employee share schemes are set out in Note 37 to the financial statements.
Shares are also held by The Company has made qualifying third-party indemnity the Hikma Pharmaceuticals Employee benefit Trust EBT provisions for the benefit of its Directors, which were made and are detailed in Note 34 to the financial statements.
during the year and remain in force at the date of this report.
The EBT has waived its right to vote on the shares it holds These indemnities are uncapped in amount in relation to and also to its entitlement to a dividend.
losses and liabilities which Directors may incur to third At the Annual General Meeting on 15 May 2008, the parties in the course of the performance of their duties.
Directors were authorised to issue relevant securities up Substantial shareholdings to an aggregate nominal amount of 6,276,920, and to be empowered to allot equity securities for cash on a non As at the date of this document, the Company had been pre-emptive basis up to an aggregate nominal amount of notied pursuant to sections 89A to 89L of the Financial 941,538, at any time up to 14 August 2009.
The Directors Services and Markets Act 2000 and Rule 5 of the Disclosure propose to renew these authorities at the Annual General and Transparency Rules of the UKLA of the following Meeting to be held on 14 May 2009 for a further year.
interests in the voting rights attaching to shares in the capital In the year ahead, other than in respect of the Companys of the Company: obligations to satisfy rights granted to employees under its Name of shareholder Number of shares Percentage held various share-based incentive arrangements, the Directors Darhold Limited 57,183,028 30.22% have no present intention of issuing any of the authorised but unissued share capital of the Company.
Messrs Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry, each The powers of the Directors are determined by its Articles being a Director and shareholder of the Company, are shareholders in the capital of Darhold Limited, Samih Darwazah, Said Darwazah and Mazen Darwazah are also of Association, the Combined Code and other relevant UK Directors of Darhold Limited.
Directors powers are detailed in the Corporate Governance report starting on page 72.
The articles give the Directors the power to appoint and remove Directors and they also provide for re-election at three year intervals.
The power to issue and allot shares contained in the Articles, are subject to shareholder approval at each annual general meeting.
The articles, which are available on the website, may be amended by special resolution of the shareholders.
qxp 1 4 09 23:54 Page 80 80 Hikma Pharmaceuticals PLC Governance Annual report 2008 Directors report continued The Takeover Code Rule 9 Auditors At the Annual General Meeting held on 6 June 2007, a vote Each person who was a Director of the Company at the date of the independent shareholders of the Company approved when this report was approved confirms that: the award of up to an aggregate of 437,141 Ordinary Shares pursuant to the Companys 2006 Long-Term Incentive so far as the Director is aware, there is no relevant audit Plan to Said Darwazah and Mazen Darwazah the LTIP information of which the Companys auditors are unaware: Holders.
Because of the relationship of the LTIP Holders and with Darhold Limited, who at the time of the Annual General the Director has taken all the steps that he ought to have Meeting held 52,649,972 Ordinary Shares at 25 April 2007 taken as a Director to make himself aware of any relevant representing 31.129%.
of the issued share capital of the audit information and to establish that the Companys Company, and as at 16 March 2009 being the latest auditors are aware of that information.
practicable date prior to the publication of this document, holding 57,183,028 Ordinary Shares, representing 30.22% This conrmation is given and should be interpreted in of the issued share capital of the Company, each of the LTIP accordance with the provisions of section 234ZA of the Holders together with certain other identied individuals Companies Act 1985. at that date was treated as acting in concert with Darhold Deloitte LLP have expressed their willingness to continue Limited for the purposes of the Takeover Code the Concert in ofce as auditors and a resolution to re-appoint them will Party.
As at 25 April 2007, the Concert Party held, in be proposed at the forthcoming Annual General Meeting.
aggregate, interests in 60,550,416 Ordinary Shares in the capital of Hikma then representing 35.800% of the then Annual General Meeting issued share capital of the Company.
As at 16 March 2009 The Annual General Meeting of the Company will be held at being the latest practicable date prior to the publication 88 Wood Street, London, EC2V 7RS on Thursday, 14 May of this document, the Concert Party held, in aggregate, 2009, starting at 11.00 a. m. The Notice convening the interests in 66,097,758 Ordinary Shares in the capital of meeting is given in a separate document accompanying this Hikma representing 34.917% of the then issued share document, and includes a commentary on the business of capital of the Company.
On full exercise of the options the AGM, and notes to help shareholders exercise their rights under the Hikma Pharmaceuticals 2004 Stock Option Plan at the meeting.
the 2004 Plan and full vesting of the LTIPs, the Concert Party would potentially have, in aggregate, interests in Approved by the Board of Directors on 16 March 2009 and 67,077,258 shares in the capital of the Company signed on its behalf by representing 35.252% of the enlarged issued share capital of the Company, on the basis that no Ordinary Shares were issued other than pursuant to the exercise of such options or Henry Knowles Company Secretary vesting of LTIPs.
16 March 2009 During the period from the Annual General Meeting in 2007 to 16 March 2009, the LTIP Holders together with other members of the Concert Party who hold options over Ordinary Shares pursuant to the 2004 Plan the Option Holders have exercised, in aggregate, options over 1,000,000 Ordinary Shares in the capital of the Company, of which 200,000 Ordinary Shares were sold immediately upon exercise, and 480,000 Ordinary Shares were retained and 320,000 were retained but subsequently disposed of by the Options Holders.
